Retroperitoneal and Truncal Sarcomas: Prognosis Depends Upon Type Not Location

Pérez, Eduardo A.; Gutierrez, Juan C.; Moffat, Frederick L.; Franceschi, Dido; Livingstone, Alan S.; Spector, Seth A.; Levi, Joé U.; Sleeman, Danny; Koniaris, Leonidas G.

doi:10.1245/s10434-006-9255-x

Cited by 64 publications

(63 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Certain previous studies support the above argument and indicate that if the liposarcoma invaded the kidney, then combined resection of the kidney is necessary (9,25). There is no evidence that chemotherapy or radiotherapy improve survival rates (26). In the present study, no patients in the studied literature were administered chemotherapy or radiotherapy.…”

Section: Discussionmentioning

confidence: 55%

Management of retroperitoneal liposarcoma: A case report and review of the literature

et al. 2015

View full text Add to dashboard Cite

Abstract. Retroperitoneal liposarcoma is a rare tumor with an incidence of 2.5 per million individuals. Early diagnosis is difficult as there is an absence of specific clinical presentations. The present case study reports a patient diagnosed with retroperitoneal liposarcoma who was treated by complete surgical resection and relapsed 3 months following the surgery. In addition, the clinical data of 14 patients with retroperitoneal liposarcoma were reviewed and analyzed. The mean age of the 14 patients at presentation was 54.1 (range, 36-73 years) and 5/14 patients experienced recurrence, ranging between 1 and 10 times. Of the 12 cases that reported histological subtypes, 7 were well-differentiated liposarcoma, 2 were dedifferentiated liposarcoma, 2 were myxoid liposarcoma and 1 was mixed subtype. All the patients underwent complete resection and 5 received combined multiple organs resection (3 nephrectomy, 1 sigmoid colon and 1 multiple visceral organs). However, no patients received chemotherapy or radiotherapy. In conclusion, retroperitoneal liposarcoma is a rare disease with a high rate of recurrence. Complete resection is the predominant treatment and combined resection of adjacent organs is occasionally necessary.

show abstract

Section: Discussionmentioning

confidence: 55%

Management of retroperitoneal liposarcoma: A case report and review of the literature

et al. 2015

View full text Add to dashboard Cite

show abstract

“…However, because these studies were done in select patients at specialized centers, it is still uncertain how the introduction of imatinib has impacted survival on a broader level within the U.S. population. Previous population-based data have suggested an improvement in survival after 2000 in patients with gastrointestinal mesenchymal neoplasms (35). However, this study was done using a heterogeneous sample population with various stages of disease and a variety of histologies other than gastrointestinal stromal tumor, including other gastrointestinal smooth muscle tumors and nerve sheath tumors.…”

Section: Discussionmentioning

confidence: 99%

Metastatic Gastrointestinal Stromal Tumors in the Era of Imatinib: Improved Survival and Elimination of Socioeconomic Survival Disparities

Artinyan

Kim

Soriano

et al. 2008

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Imatinib was approved in 2002 for unresectable and metastatic gastrointestinal stromal tumors. Our objective was to determine if the introduction of imatinib coincided with improved survival from metastatic gastrointestinal stromal tumor in the U.S. population and in specific socioeconomic groups. Methods: Query of the Surveillance, Epidemiology, and End Results registry identified 552 patients with metastatic gastrointestinal stromal tumor between 1995 and 2004. Year of diagnosis was categorized into two periods,

show abstract

“…In the report by Perez et al, a recent meta-analysis of the pertinent literature regarding retroperitoneal soft tissue sarcomas failed to show significant radiotherapy-related survival benefits in the treatment retroperitoneal liposarcoma [9] . Matsushita et al reported that chemotherapeutic agents such as doxycycline and ifosfamide demonstrating activity against metastatic sarcoma, but such chemotherapeutic agents have not shown survival benefit [5] .…”

Section: Discmentioning

confidence: 99%

Liposarcoma arising from the right renal sinus with inferior vena caval involvement

Kobayashi¹,

Nakayama

Matsuzaki

et al. 2015

JST

View full text Add to dashboard Cite

A woman aged 55 was introduced to our medical center for retroperitoneal tumor incidentally discovered by screening computerized tomography. Imaging showed a round fatty tumor extending into the right kidney and infiltrating into the inferior vena cava and no distant metastasis. We extirpated the tumor and tumor thrombus infiltrating the inferior vena cava along with the right kidney en bloc. Pathological examination showed well-differentiated liposarcoma that we believe had arisen from the renal sinus. Liposarcoma arising from the renal sinus with intravenous involvement is distinctly rare. Treatment by complete resection is recommended.

show abstract

Retroperitoneal and Truncal Sarcomas: Prognosis Depends Upon Type Not Location

Cited by 64 publications

References 26 publications

Management of retroperitoneal liposarcoma: A case report and review of the literature

Management of retroperitoneal liposarcoma: A case report and review of the literature

Metastatic Gastrointestinal Stromal Tumors in the Era of Imatinib: Improved Survival and Elimination of Socioeconomic Survival Disparities

Liposarcoma arising from the right renal sinus with inferior vena caval involvement

Contact Info

Product

Resources

About